In 174 women with stage III HER2-negative HRD breast cancer, intensified alkylating chemotherapy with stem cell rescue gave no 4-year overall survival advantage over chemotherapy then olaparib (77.0% vs 76.4%; HR 1.11), with more serious adverse events (47% vs 26%).
RCTn = 174
Seefat et al. Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial